Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 24, 2024
Product Development
Clinical Report: Merus data stand out among ASCO highlights
Clinical data released ahead of ASCO from Merus, Caribou, BioNTech and more
BioCentury | Mar 8, 2024
Product Development
Pfizer blends modality tools in new vision for oncology unit
Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen
BioCentury | Mar 5, 2024
Discovery & Translation
Distillery spotlight: new Alzheimer’s mechanisms from academia
BioCentury’s survey of the 2023 translational literature highlights a cluster of neuron-targeting mechanisms for Alzheimer’s disease
BioCentury | Oct 2, 2023
Regulation
Oct. 2 Quick Takes: Takeda withdrawing Exkivity after confirmatory miss
Plus: Novartis’ iptacopan shows benefit in IgA nephropathy and updates from Mirum, Lexeo, Rocket, Lilly, Syndax, SAB, Amicus and Pneumagen
BioCentury | Apr 21, 2023
Product Development
ADC advances at AACR: target diversity, optimizing internalization
BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
BioCentury | Mar 13, 2023
Deals
Pfizer believes $43B Seagen deal positions it to fulfill most of 2030 revenue goal
Provided regulators clear deal, pharma sees $10B+ in added revenue from ADC company by early next decade
BioCentury | Mar 13, 2021
Translation in Brief
NIH identifies antisense oligos to treat progeria; plus epigenetic gene therapies for chronic pain and Cend’s pancreatic cancer therapy
BioCentury’s roundup of translational news
BioCentury | Aug 28, 2020
Distillery Therapeutics
Preventing thrombosis using nanoparticles loaded with anti-G protein peptides
DISEASE CATEGORY: Cardiovascular
INDICATION: Ischemia/reperfusion injury Nanoparticles loaded with a peptide inhibitor of GNA13, a G protein subunit, could treat cardiac ischemia/reperfusion injury.
INDICATION: Ischemia/reperfusion injury Nanoparticles loaded with a peptide inhibitor of GNA13, a G protein subunit, could treat cardiac ischemia/reperfusion injury.
Items per page:
1 - 10 of 55